

Multimodal BEHRT: Transformers for Multimodal Electronic Health Records to predict breast cancer prognosis

Ndèye Maguette Mbaye 1,2,3 , Michael Danziger 4 , Aullène Toussaint 2,6 , Elise Dumas 1,3,6 , Julien Guerin 9 , Anne-Sophie Hamy-Petit 2,6 , Fabien Reyal 6,7,8 , Michal Rosen-Zvi 4,5 and Chloé-Agathe Azencott 1,2,3*

- ¹CBIO-Centre for Computational Biology, Mines Paris, PSL Research University, Paris, France
- ²Institut Curie, PSL Research University, Paris, France
- ³U900, Inserm, Paris, France
- ⁴Al for Accelerated Healthcare and Life Sciences Discovery, IBM Research Lab Israel, Haifa 3498825, Israel
- 5 The Hebrew University of Jerusalem, Ein Kerem Campus, Jerusalem, Israel
- ⁶Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France
- ⁷Department of Surgical Oncology, Institut Curie, University of Paris, Paris, France
- ⁸Department of Surgery, Institut Jean Godinot, Reims, France

Correspondence*: Corresponding Author chloe-agathe.azencott@minesparis.psl.eu

2 ABSTRACT

- 3 **Background** Breast cancer is a complex disease that affects millions of people and is the leading
- 4 cause of cancer death worldwide. There is therefore still a need to develop new tools to improve
- 5 treatment outcomes for breast cancer patients. Electronic Health Records (EHRs) contain a
- 6 wealth of information about patients, from pathological reports to biological measurements,
- 7 that could be useful towards this end but remain mostly unexploited. Recent methodological
- 8 developments in deep learning, however, open the way to developing new methods to leverage
- 9 this information to improve patient care.
- 10 Methods In this study, we propose M-BEHRT, a Multimodal BERT for Electronic Health Record
- 11 (EHR) data based on BEHRT, itself an architecture based on the popular natural language
- 12 architecture BERT (Bidirectional Encoder Representations from Transformers). M-BEHRT models
- multimodal patient trajectories as a sequence of medical visits, which comprise a variety of
- information ranging from clinical features, results from biological lab tests, medical department
- and procedure, and the content of free-text medical reports. M-BEHRT uses a pretraining task
- analog to a masked language model to learn a representation of patient trajectories from data
- 17 that includes data that is unlabeled due to censoring, and is then fine-tuned to the classification
- 18 task at hand. Finally, we used a gradient-based attribution method -to highlight which parts of the
- 19 input patient trajectory were most relevant for the prediction

⁹ Data Office, Institut Curie, 26, rue Ulm 75248 PARIS, France.

Mbaye et al. Multimodal BEHRT

- 20 **Results** We apply M-BEHRT to a retrospective cohort of about 15 000 breast cancer patients
- 21 from Institut Curie (Paris, France) treated with adjuvant chemotherapy, using patient trajectories
- 22 for up to one year after surgery to predict disease-free survival (DFS). M-BEHRT achieves an
- 23 AUC-ROC of 0.77 [0.70-0.84] on a held-out data set for the prediction of DFS 3 years after surgery,
- 24 compared to 0.67 [0.58-0.75] for the Nottingham Prognostic Index (NPI) and for a random forest
- 25 (p-values = 0.031 and 0.050 respectively).
- In addition, we identified subsets of patients for which M-BEHRT performs particularly well such
- 27 as older patients with at least one lymph node affected.
- 28 **Conclusion** In conclusion, we proposed a novel deep learning algorithm to learn from multimodal
- 29 EHR data. Learning from about 15 000 patient records, our model achieves state-of-the-art
- 30 performance on two classification tasks. The EHR data used to perform these tasks was more
- 31 homogeneous compared to other datasets used for pretraining, as it exclusively comprised
- 32 adjuvant treated breast cancer patients. This highlights both the potential of EHR data for
- 33 improving our understanding of breast cancer and the ability of transformer-based architectures
- 34 to learn from EHR data containing much fewer than the millions of records typically used in
- 35 currently published studies. The representation of patient trajectories used by M-BEHRT captures
- 36 their sequential aspect, and opens new research avenues for understanding complex diseases
- 37 and improving patient care.
- 38 Keywords: electronic health records, breast cancer, relapse prediction, transformers, keyword, keyword, keyword, keyword

1 INTRODUCTION

- 39 Breast cancer is by far the most commonly diagnosed cancer among women (almost 2.3 million cases
- 40 worldwide in 2022) and the leading cause of cancer death worldwide (1).
- 41 Among the various treatment options, adjuvant chemotherapy is proposed to patients after first-line
- 42 surgery to lower the chance that the cancer will return. It is a widely used treatment option, and is offered
- 43 in many cases, unless the tumor was small, did not show sign of aggressiveness, and no lymph nodes were
- 44 affected. However, recurrence or death are still possible. Accurately identifying the patients most likely
- 45 to relapse is therefore important to inform both treatment selection and future research to propose better
- 46 therapeutic options.
- 47 One of the most commonly used prognostic tools for breast cancer is the Nottingham Prognosis Index
- 48 (NPI), which uses a combination of three clinical features (tumor size, tumor grade, and number of lymph
- 49 nodes) and was proposed in 1982 (2). Since then, many authors have used statistical and machine learning
- 50 algorithms to build breast cancer relapse predictors from clinical features; however NPI still seems to be
- 51 the most robust criterion (3), despite its limitations.
- In the quest for improving the future outcome of patients, there has been a growing interest over the
- 53 years for including information besides clinical features into prognostic tools. These modalities include
- 54 biological measurements (4), magnetic resonance imaging (5), ultrasound images (6), histopathological
- 55 images or gene expression data (7). The papers cited show that combining different modalities improves
- 56 prediction performance.
- However, these modalities are not always available for all patients treated. For this reason, other authors
- 58 have taken advantage of the considerable information present in medical reports that constitute the EHR of
- 59 patients, using named entity recognition techniques to extract relevant terms from clinical notes (8, 9).

Multimodal BEHRT

Among those, transformer-based models inspired by BERT (Bidirectional Encoder Representations from Transformer) (10), an architecture that has significantly outperformed previous methods on a large variety of natural language processing tasks and continues to drive advancements in the field, have recently gathered a lot of interest. Their superiority is explained by the use of self-supervised pretraining tasks, such as masked language modeling and next sentence prediction, which allows them to learn better representations of the data. These architectures have been successfully transposed to patient trajectories by seeing them as sequences of medical events rather than of words (11, 12, 13, 14, 15). To the best of our

knowledge, however, none of these have considered cancer-related clinical outcomes, possibly because

they are typically applied to very large cohorts of millions of patients.

In this paper, we present several new transformer architectures for predicting clinical outcomes from multimodal EHR data, which consider patient trajectories as sequences of medical visits represented by both tabular data (clinical features, biological measurements, therapies, nature of the visit) and free-text medical reports. We evaluate our proposed method on the prediction of disease-free survival in breast cancer, on a cohort of several thousands of patients. We pretrain the models on the equivalent of a masked language model, which can also be trained on records excluded from the classification training set because they were censored.

2 MATERIALS AND METHODS

76 **2.1 Data**

Mbave et al.

60 61

62 63

64

65

66

67

68

- In this work, we used data extracted from the EHR system from Institut Curie in Paris (France). All data collected were pseudonymized. Additionally, individuals under 18 years of age, with a history of previous cancer, under guardianship, or unable to provide consent were excluded from this study. Every patient included in the study has completed and signed a research informed consent form. The study was approved by the Breast Cancer Study Group of Institut Curie and was conducted according to institutional and ethical rules concerning research on tissue specimens and patients.
- We built a data base of 15 150 unique patients, treated with adjuvant chemotherapy for breast cancer between 2005 and 2012. The data base contains general descriptors of patients (such as age, sex, or weight) as well as information about each visit in their medical record: clinical information such as tumor size or cancer subtype, biological markers (tumor markers, counts of leukocytes and their subtypes) if they were measured, treatment information, and free-text notes. Finally, the patients are annotated with survival and recurrence information.
- Free-text notes are unstructured narrative descriptions or notes entered by healthcare professionals. Unlike the structured data, which is organized into predefined fields, free text allows healthcare providers to input progress reports and relevant patient information recorded during patient journey, in a more natural manner. Free text reports from cytopathology or radiology also capture key information from medical images, as captured by experts. Those medical reports comprise free-text clinical notes for consultations, as well as free-text reports of cytopathology, radiology, surgery, and blood tests. All reports are written in French.

95 2.2 Preprocessing

96 2.2.1 Tabular data preprocessing

We first describe how we processed the structured or tabular, a.k.a structured, data describing each medical event for each patient.

Multimodal BEHRT

2.2.1.1 Biological measurements

- 100 From biological measurements, we only kept features that have less than 30% of missing values: MONO,
- 101 LEUK, LYMP, PN and CA 15-3. All numerical values have to be discretized to enable tokenization. We
- 102 binarized biological measurements into two values: 1 if the value is outside the normal range for the
- 103 biological measurement, and 2 otherwise. Figure S1 in the Supplementary Material shows the distribution
- 104 of biological measurements; the medical normal range of these biological features can be found in Table S1
- 105 in the Supplementary Material.
- In addition, we also computed the differences $\Delta_t = v_t v_{t-1}$ between the current visit's biological
- 107 value v_t and the previous visit's value v_{t-1} . We then discretized the Δ values by dividing them by ten
- and rounding. This captures more subtle variations in biological measurements evolution than the mere
- 109 abnormal/normal values.

Mbaye et al.

110 2.2.1.2 Clinical information

- 111 From the clinical information, we included both longitudinal and non-longitudinal features: age,
- 112 undergone therapies, and tumor size on the one hand, tumor grade and number of nodes involved at
- 113 diagnostic as well as breast cancer molecular subtypes (Luminal, TNBC, HER2+/RH-, HER2+/RH+) on
- the other. Age is computed at each visit and discretized by rounding to the nearest integer. Descriptive
- 115 statistics of the age, breast cancer subtype, grades, number of lymph nodes involved, tumor size and
- 116 biological measurements are given in Table S1 in the Supplementary Material.
- We combined tumor size, tumor grade and the number of lymph nodes involved into the NPI (2),
- 118 a commonly used, clinically relevant and robust prognostic tool (3). The NPI is computed as NPI =
- 119 $0.2 \times \text{tumor_size}$ (cm) + tumor_grade + lymph_nodes_stage, where the lymph nodes stage is computed as
- 120 1 (0 nodes), 2 (1 to 3 nodes) or 3 (> 3 nodes). The lower the score, the higher the chance of survival 5 years
- 121 after surgery. The tumor size is measured at various points in the cancer journey. We kept for this study the
- 122 clinical tumor size assessed at diagnosis when the tumor is palpable, and the pathological tumor size which
- 123 is the histological size of the tumor extracted at the surgery. The NPI is recalculated with each new tumor
- size measurement, hence termed as the dynamic NPI (dNPI). For patients with at least one available feature
- among the three required for calculating the dNPI, we imputed missing tumor sizes using the mode value
- among samples of the same clinical or pathological tumor stage (TNM) status. The number of involved
- 127 lymph nodes is the sum of the number of affected sentinel nodes and axillary nodes. We imputed missing
- 128 number of nodes to zero and missing tumor grade to G2 (grade 2), based on the most frequent values in our
- 129 data. The higher the dNPI, the lower the chance of survival.
- Following Blamey et al. (16), we categorized dNPI into six prognostic groups (PG): Excellent (EPG)
- 131 (NPI \leq 2.4), Good (GPG) (2.4 < NPI \leq 3.4); Moderate I (MPG I) (3.4 < NPI \leq 4.4), Moderate II (MPG
- 132 II) (4.4 < NPI < 5.4), Poor (PPG) (5.4 < NPI < 6.4) and Very Poor (VPPG) (NPI > 6.4).
- Because M-BEHRT can handle missing values (see Section 2.3.1), we did not impute missing values for
- 134 longitudinal features. However, for the baselines, we opted to impute the tumor size, number of nodes,
- 135 grades and cancer subtype by an aberrant value of 999. Using an aberrant value allows the model to
- 136 explicitly identify and differentiate imputed values from the actual data, by analogy with not locating a
- token within a sentence when using M-BEHRT.

Multimodal BEHRT

2.2.1.3 Therapies, department and procedure

- 139 Therapies are inferred by considering the occurrence date for the surgery, the start and end dates for
- 140 hormone-therapy, chemotherapy and anti-HER2 treatment, and the number of doses administered for the
- 141 radiotherapy. This inference incorporates the therapeutic protocol of Institut Curie (see Figure S2 in the
- 142 Supplementary Material). Subtherapies, also inferred from this protocol, provide additional information
- about the specific molecules given in the case of chemotherapy or anti-HER2 therapy, radiation types in
- the case of radiotherapy, and specific surgical procedures including both breast and axillary surgeries. A
- list of all possible values for the therapies and subtherapies fields is given in Table S3 in the Supplementary
- 146 Material.

Mbave et al.

- 147 Finally, medical visit department and procedure names are available within the headers of free-text
- 148 reports. We normalized department and procedure names by removing accents, punctuation and special
- 149 characters. We merged synonyms into a single word: for example, anapath, anatomopathologie and
- 150 anatomo-cyto-pathologie are merged into anatomo-cyto-pathologie (anatomical cytology in English). To
- 151 do so, we sifted through the corpus vocabulary, identifying and unifying synonyms and/or differently
- 152 written terms to enhance coherence of the medical history. We also removed words that appear fewer than
- 153 100 times in the whole corpus.

154 2.2.1.4 Disease-Free Survival at 3 years

- Finally, we defined a binary classification task by labeling each patient with whether they had survived
- 156 disease-free 3 years after the surgery.
- We retained patient history up to one year after first surgery and starting from 6 months before the breast
- 158 cancer diagnosis. This choice of one year after the first surgery as an index date ensures that we use as
- much of the patient's history as possible, without capturing an actual relapse. We removed patients who
- 160 relapsed before the index date, as well as patients censored before 3 years after the first surgery, as depicted
- in Figure 1. All patients had at least 3 visits in their medical history. This results in 8 089 patients, with
- 162 6.2% having a negative disease-free survival (DFS) status.
- 163 For the evaluation of our models, we held out a test set containing 520 patients, with a proportion of
- 164 negative samples (6.1%) similar to that of the whole data set. For pre-training tasks requiring no labels (see
- 165 Section 2.3.2), we used all patients and their full history.

166 2.2.2 Free-text reports preprocessing

- 167 Free-text reports represent unstructured textual descriptions of medical information recorded by medical
- 168 experts. They can be clinical notes, that is to say, information recorded during patient encounters with
- 169 clinicians, or reports made by specialists (laboratory biologists, radiologists, histopathologists) to interpret
- 170 the results of medical exams. The average number of visits, reports, and words per report in our data are
- 171 given in Table S1 in the Supplementary Material.
- Unlike tabular data, that is recorded in a standardized way at least within a hospital, medical reports are
- 173 highly variable, as they allow each healthcare provider to be distinctive in format, style, or terminology.
- 174 Moreover, the semantic related to the medical field is complex, using abbreviations, acronyms, and
- 175 medical jargon (17). Therefore, in addition to common NLP preprocessing steps (normalization, removal
- 176 of noisy entities, adverbs, stopwords and text delimiters), our text preprocessing pipeline includes steps
- 177 that are specific to medical reports. The full text preprocessing pipeline is described on Figure S3 in the

Mbaye et al. Multimodal BEHRT




Figure 1. Flowchart of study inclusion and exclusion.

Supplementary Material, and we describe in Text S1 in the Supplementary Material the steps that are specific to clinical text.

180 2.3 Multimodal BEHRT

181

182

183

184 185

186

187

188

Information retrieved from EHR are generally time stamped events. In this study, this information is organized as structured or tabular data (for numerical values) collected over time, along with a series of free-text medical reports throughout the patient's journey. As in Natural Language Processing, EHR can be transformed into sequences of tokens, where each token represents a unit of information from the EHR rather than a linguistic unit. These sequences can then be fed into language models such as transformers (18). This was first proposed by Li et al. (11), who introduced BEHRT (BERT for EHR), an architecture based on that of BERT (Bidirectional Encoder Representations from Transformers) (10) to predict future conditions from a sequence of diagnoses.

Here we propose Multimodal-BEHRT (M-BEHRT), which combines two transformer-based deep learning models of architecture inspired by BEHRT's: Tabular BEHRT and Text BEHRT. Tabular BEHRT considers

Mbaye et al. Multimodal BEHRT

- 191 that each medical visit is described using structured data: the department in which it took place, the
- 192 corresponding procedure, as well as clinical and biological measurements available at this time. Like BERT
- and BEHRT, Tabular BEHRT combines a pre-training task (Masked Language Model) with a downstream
- 194 task (the classification task), but applies it to a multimodal EHR tabular dataset. Text-BEHRT considers
- 195 that each medical visit is represented by a free-text medical report. Text BERT uses adapted pretrained
- 196 embeddings to build a sequence that serve as input for the classification task. M-BEHRT is a meta-model
- 197 that combines Tabular BEHRT and Text BEHRT through a cross-attention module (19).
- In what follows, we first describe how we construct patient trajectories (Section 2.3.1 from multimodal
- 199 tabular data (Section 2.3.1.1) as well as free-text reports (Section 2.3.1.2). We then describe in Section 2.3.2
- 200 the self-supervised approach used for learning embeddings of multimodal patient trajectories, and in
- 201 Section 2.3.3 the architecture we propose for the binary classification of patient trajectories. Finally, we
- 202 describe the baselines used to evaluate our models in Section 2.4.
- 203 2.3.1 Multimodal sequence construction

204 2.3.1.1 Patient trajectory representation from structured data

- By analogy with Natural Language Processing data, a patient's history can be seen as a document, where
- 206 visits serve as sentences, and the events within the visits act as tokens. In our final data, the medical
- 207 sequence consists of a sequence of visits that are chronogically ordered.
- We used dates from the medical reports to construct medical chronological sequences. Each visit is
- 209 described by the specific department and procedure from which the report originates, which contextualizes
- 210 additional features, which are incorporated as available.
- As illustrated on Panel A of Figure 2, each visit is therefore described by at most 17 features: biological
- 212 measurements that include binary values and deltas of measurements of the 5 biological markers, the
- 213 medical department where the visit took place, the type of procedure the visit corresponded to, the therapy
- and sub-therapy administered, the patient's age, the dNPI and the breast cancer subtype (which is static but
- 215 repeated at each visit).
- A separate modality layer indicates what kind of feature each measurement corresponds to. Generally
- 217 speaking, this could be set to simply indicating the modality (biological, clinical, visit), but here we chose
- 218 to be specific and encode the feature name. This allows us in particular to deal with missing values, which
- 219 can simply be skipped as the modality layers provides the information of what feature is at each position.
- 220 The modality layer allows the algorithm to treat each modality differently.
- As in BERT and BEHRT, a sequence of visits starts with the special token CLS, and visits are separated
- 222 with the special token SEP.
- Whereas BEHRT captures temporal information by including the age of the patient in a separate layer,
- 224 we kept age as other clinical descriptors in the main input layer, but added another special embedding layer
- 225 that represents the delay between the next visit and the previous. We discretized delays, as in Pang et al.
- 226 (12), into W0-3 (under 1, 2, 3, or 4 weeks) for delays shorter than 4 weeks, M1-12 (under 1 month up to
- 227 under 12 months) for delays shorter than a year and LT (long term) for delays longer than a year.
- One of the notable constraints in BERT-like models is token capacity: they process tokens in fixed-size
- 229 sequences of at most 512 tokens. While this size is arbitrary and varies depending on the exact BERT
- 230 architecture and implementation, it cannot take much larger values, as it is linked to the memory usage of
- 231 the self-attention mechanism of BERT, which grows quadratically with the number of tokens (each token

Multimodal BEHRT Mbaye et al.

being attentive to every other token). There is therefore a tradeoff between the number of features/tokens 232 used to describe each visit, and the number of visits that can be considered. This is alleviated by the exclusion of both missing values and biological delta values equal to zero (corresponding to an absence of change in measurement), which is possible as the modality layer informs the architecture as to the kind of feature each token corresponds to. In practice, if the patient trajectory still exceeds 512 tokens, we only consider the first 512 tokens, which represent the initial interactions of the patient with the healthcare system, and inform about initial diagnostic visits and treatment decisions. Figure S4 in the Supplementary Materials shows how much information is excluded from patient trajectories due to restricting data to the 512 first tokens.

241 Panel A of Figure 2 illustrates this representation of patient trajectories based on tabular data.

Patient trajectory representation from free text

233

234 235

236

237

238

239

240

251

252

253

254 255

256

257

258

259

260

261

262

263

264

265

271

243 In addition, we assume that important information is contained within the text itself of the free-text reports. We therefore build a sequence of free-text reports, ordered chronologically from the date of the 244 245 diagnosis until the index date (one year after the first surgery). As shown in Table S2 in the Supplementary Material, the number of reports per patient and the length of each report are such that these create very 246 long documents (on average 34 reports, averaging 159 words each, for a total of more than 5 000 words 247 248 per patient history). However, while BERT has proven to be highly effective in capturing contextual 249 relationships and semantic nuances in text, it can only process sequences of at most 512 tokens, due to the memory footprint of the self-attention mechanism. 250

This constraint again poses challenges when dealing with lengthy documents such as a sequence of medical reports (20). Using transformers to classify long documents is still a topic of open research (21). The most straightforward approach consists in truncating inputs to fit within the allowed number of tokens, typically by using the first, last or middle tokens. However, limiting patient history to 512 tokens may result in major information loss and hence produce incomplete representation of medical reports. Other approaches such as Big Bird (22) or Nyströmformer (23) use sparse or low-rank approximations of the self-attention matrices. However, existing pretrained models typically do not handle more than 4096 tokens, which is still too short for some of the patients in our data set. In addition, they have only been trained on English corpora whereas our medical notes are in French. Nevertheless, our corpus is much too small to train a transformer model from scratch. Finally, many approaches consist in dividing long text into chunks smaller than 512 tokens and combining their embeddings, whether through an additional layer of self-attention in a hierarchical model (24) or by pooling (25). In the absence of a clear consensus on which of these strategies is likely to perform best (21, 25), we chose here to use a simple aggregation strategy. More specifically, we construct the embedding of every report by summing the embeddings of all tokens it contains, and construct sequences not of token embeddings, but of reports embeddings.

We obtain token embeddings from DrBERT (26), a state-of-the-art transformer model, based on the 266 RoBERTa architecture (27) and trained on a French biomedical corpus which contains 7GB of clinical 267 data from multiple sources. We can then train a BERT model on the sequences of reports embeddings. 268 To account for temporality, we add an embedding layer of delays between reports. Finally, we use BERT 269 special tokens: CLS for the start of a medical history and SEP to separate reports from different visits. This 270 representation is illustrated on Panel B of Figure 2.

Multimodal BEHRT

2.3.2 Pretraining task

- 273 To improve the embeddings of patient trajectories built from structured data, we follow the example
- 274 of BEHRT and pre-train a Masked Language Model (MLM) on the representations described in
- 275 Section 2.3.1.1.

Mbave et al.

- As in Natural Language Processing, the MLM is designed to predict missing or masked tokens within a
- 277 patient's history, using the bidirectionaly context provided by the surrounding tokens. Its goal is to learn
- 278 contextual representation of the medical events in the patient's history. For this purpose, in this pre-training
- 279 phase Tabular-BEHRT uses the whole cohort of 15 150 patients and the entire sequence of events for each
- 280 patient, from the date of diagnosis to the date of death or censorship, with a length average of $506(\pm 466)$
- tokens. We randomly replaced 15% of the tokens with a special MASK token. We swapped another 2%
- 282 with another token at random; this adds a limited amount of noise, encouraging the model to learn a more
- 283 robust and generalizable representation of patient trajectories. As shown on Panel C of Figure 2, the MLM
- 284 part of M-BEHRT is a transformer-based architecture that generates probabilities for each token in the
- 285 vocabulary, computed using softmax over the model's output logits, as a multilabel learning task.
- We first split the dataset into a training (90%) and a validation set (10%) in order to prevent overfitting.
- 287 Then, all the embeddings from the training set are randomly initialized and fed to the MLM. We use
- 288 Bayesian optimization to find the best set of hyperparameters, with precision as a criterion. For robustness,
- 289 we run the model five times with five different random seeds for the sequence masking, and use as final
- 290 token embeddings for the downstream classification tasks the mean values of standardized embeddings
- 291 from these five runs.
- 292 The pretraining task solely concerns tabular data, to establish effective representations of tabular events
- 293 within the patient trajectory. For text data, running an MLM on the whole medical corpus would require
- 294 more computational resources than available.

295 2.3.3 Binary Classification

- We now describe the architecture of M-BEHRT, a deep neural network to learn binary classifiers from
- 297 patient trajectories. M-BEHRT is the combination of two architectures: Tabular BEHRT, which learns from
- 298 patient trajectories built from structured data; Text BEHRT, which learns from patient trajectories built
- 299 from free text.
- 300 Tabular BEHRT consists in using labeled data to fine-tune for classification the network obtained by
- 301 pre-training on patient trajectories built from structured data. As shown on Panel C of Figure 2, only the
- 302 last layer is different between pre-training and fine-tuning: here the patient history embeddings are fed to a
- 303 single feed-forward layer with sigmoid activation.
- The architecture of Text BEHRT is illustrated on Panel D of Figure 2. It is again a transformer-based
- 305 model, which uses report embeddings obtained through the aggregation of DrBERT embeddings as
- 306 described in Section 2.3.1.2. The same sampling strategy as the one depicted in the previous section is used
- 307 for this task.
- 308 Finally M-BEHRT combines information from tabular data and free-text reports by integrating
- 309 Tabular BEHRT and Text BEHRT using a cross-attention module (19). The cross-attention module extends
- 310 the capabilities of traditional transformer architectures to handle multiple data modalities in a unified
- 311 framework. Hence M-BEHRT is expected to harness the complementarity of the information encoded in
- 312 different modalities to improve predictive power.

Mbaye et al. Multimodal BEHRT

- As shown on Panel E of Figure 2, logits from structured data trajectories and the text trajectories are computed using their respective models. The cross-attentions layer calculates attentions with the logits as
- 315 key, value and query. Logits from Text BERHT used as query interact with logits from Tabular BERHT
- 316 that represent key and value. The loss is backpropagated to the cross-attention module. To do so, logits
- 317 must have same size. Therefore, logits from Text BEHRT are first fed through a single feed-forward layer
- 318 to obtain an embedding of the same size as logits from Tabular BEHRT.
- In contrast, cross-attention is used when there are two distinct sets of inputs. One set of inputs (the
- 320 "query") interacts with another set (the "key" and "value"). The model attends to the "key" sequence to
- 321 inform the processing of the "query" sequence. This is commonly used in models where input data needs
- 322 to interact, such as translating a sentence in one language to another.
- 323 Because the labeled data is typically imbalanced, we implemented a stratified batches strategy, which
- 324 consists in loading the same proportion of positive and negative samples for each batch, with replacement
- 325 for the positive instances (the minority class). This sampling strategy allows us to train on balanced batches.

326 2.4 Comparison baselines

- 327 To evaluate our models, we developed several comparison baselines. The first is the NPI measured
- 328 at the date of diagnosis, a tool that is currently used in the clinic to predict prognosis. In addition, we
- 329 developed baselines using classical machine learning methods: random forests classifiers (RF), logistic
- 330 regression (LR), and support vector machines (SVM). These machine learning models (RF, LR and SVM)
- 331 use the same input data as M-BEHRT, but cannot directly use sequential information. For dynamic tabular
- 332 data (procedure name, department name, binarized biological measurements), sequences of events are
- 333 transformed into number of occurences of events. Clinical features (age, therapies, tumor size, tumor grade,
- 334 breast cancer molecular subtype and number of nodes) are kept static, using their values at the time of
- 335 diagnosis. Regarding free-text reports, we created a table where each feature of the report embeddings
- 336 (of 768 dimensions) becomes a column. We imputed missing values with zero (0) for both of the inputs.
- 337 For M-BEHRT, outputs from tabular data baselines and from text data baselines (specifically their logits)
- 338 constitute inputs to a secondary model (meta-model) which makes the final prediction.
- In order to consider class imbalance and prevent the model from being biased towards the majority class,
- 340 we choosed the strategy of assigning different weights to each class during training. These weights are
- 341 inversely proportional to class frequencies in the training data. By penalizing the majority class, the model
- 342 is ensured to have enhanced performance on minority classes.

343 2.5 Model selection

- For model selection, we split the training data (8 289 patients, excluding the held-out data set of 520
- patients) into a training and a validation sets (respectively 90% and 10% of the data). For each method, we
- 346 use Bayesian optimization (28) to find the optimal set of hyperparameters, using the Average Precision
- 347 Score (APS) on the validation set as a performance criterion.

348 2.6 Computational resources

- We used Python to code models and analyses pipelines for this study, in particular scikit-learn (29) for
- 350 the classical machine learning models, hyperopt (28) for Bayesian optimization, spaCy (30) for natural
- 351 language processing tasks, and PyTorch (31) for the implementations of Tabular BEHRT, Text BEHRT and
- 352 M-BEHRT, which are built on that of BEHRT (11). The masked language model and DFS classification
- 353 model were computed on NVIDIA A40-46GB Graphical Processing Units (GPU).

Mbaye et al. Multimodal BEHRT




Figure 2. M-BEHRT architecture. Panel A: representation of patient trajectory using tabular data. Panel B: representation of patient trajectory using free-text reports. Panel C: architecture of Tabular BEHRT (learning from patient trajectories represented from tabular data as in Panel A). Panel D: architecture of Text BEHRT (learning from patient trajectories represented from free-text reports as in Panel B). Panel architecture of M-BEHRT, learning from both representations by combining Tabular BEHRT and Text BEHRT with cross attention.

3 RESULTS

354

3.1 Patient trajectory embeddings

355 3.1.1 Tabular patient trajectory embeddings

We first focus on the Masked Language Model (see Section 2.3.2) and evaluate the quality of the patient trajectory embeddings learned during the pre-training phase of Tabular BEHRT.

Mbaye et al. Multimodal BEHRT

The optimal hyperparameters we identified for the MLM are 5 hidden layers with 12 attention heads, a hidden size of 144, an intermediate layer size of 133, a training duration of 120 epochs, using Adam optimizer with a learning rate set to 1e-3 and a batch size of 64.

To assess the performance of the MLM, we ran the model five times with five different random seeds for the sequence masking. We also compute a baseline by running the MLM on a data set in which tokens have been randomly reordered within each sequence. This approach disrupts the inherent sequential structure of the data, and creates a scenario where the model should not be able to rely on contextual relationships between tokens. Hence, comparing the MLM's performance on shuffled sequences against its performance on original sequences offers a benchmark for assessing the impact of contextual information on the model's predictive capabilities. The precision of these models (proportion of correctly predicted masked tokens) on the held-out validation set is shown on Figure S5 in the Supplementary Material.

The MLM is able to predict masked tokens with a precision of 72% on the validation set, a performance that is not significantly different from the one on the training set, highlighting the absence of overfitting. In addition, this precision is significantly higher than the precision of 55% obtained when shuffling the sequences, which shows that the MLM does indeed capture contextual information. We also note that the precision of the MLM of BEHRT reported by Li et al. (11) on sequences of diagnoses is of 66%. While it is difficult to compare this performance to ours due to the different nature of the tasks, it indicates that the MLM provides embeddings of sufficient quality to perform supervised learning in a second stage.

We further evaluate embeddings generated by the MLM by visualizing token embeddings through two-dimensional plotting along the first two components of a t-distributed Stochastic Neighbor Embedding (t-SNE) as shown on Figure 3. This figure shows how the MLM capture semantic relationships between tokens and contextual information. Tokens belong to the same modality (therapies, variation in biological features, breast cancer subtypes) tend to cluster together, with the exception of procedures and departments, which tend to be mixed together. This is however unsurprising, as some procedures and departments are tightly linked; for example, panel F shows that the embedding of the "nuclear medicine" service is quite close to the embeddings of "radiology", "scanner" and "MRI" procedures, while panel D shows that the embedding of the "radiotherapy" service is quite close to the embeddings of several procedures all relating to the proposal, prescription, initiation, unfolding and ending of treatment by radiotherapy.

3.1.2 Medical reports embeddings

We first evaluate the quality of the medical reports embeddings obtained by pooling tokens embeddings extracted from DrBERT by visualizing them after their projection into a 2D space using t-SNE. The proximity of reports within this space corresponds to their semantic similarity. As shown in Figure 4, this visualization provides a comprehensive overview of the clustering patterns, demonstrating the potential of DrBERT embeddings in representing French medical text data.

This figure shows clusters of reports written in the same departments. Additionally, it display promixity between clusters that arise from similar departments. The Panel A groups all reports associated with radiology, including "mammography", "MRI", "ultrasound", or "scintigraphy". The same pattern is observed in Panel D, which contains the "generic" reports as those related to "discharge", "external care" or "information", and in Panel B, with clusters relating to cytology ("anatomocytopathology", "cytology").

397 Lastly, Panel C displays reports from various departments positioned closely together.

Mbaye et al. Multimodal BEHRT




Figure 3. t-SNE of Tabular BEHRT tokens embeddings as learned by the Masked Language Model. Panels A through F zoom in on specific section of the plot. Panel A corresponds to a cluster of deltas in biological measurements. Panel B shows that age tokens cluster together. Panel C shows that therapy token, on the one hand, and breast cancer subtypes, on the other, cluster together. Panel D and F show two different clusters of procedures and departments. Panel E show that dNPI tokens cluster together, as well as BERT special tokens.

Mbaye et al. Multimodal BEHRT




Figure 4. t-SNE of Text BEHRT medical reports embeddings. Each panel correspond to a different departments' reports with similar information, cluster together.

3.2 DFS prediction

398

399

3.2.1 Comparison of M-BEHRT with baselines

We report on Figure 5 the ROC curves on the test set of M-BEHRT trained with optimal hyperparameters (see Section 2.5; learning rate of 10^{-3} , batch size of 64, Adam optimizer, 6 epochs of training), as well as of the comparison baselines described in Section 2.4.

Figure 5 shows that all methods perform significantly better than a random classifier (AUC-ROC of 0.5).

404 Moreover, M-BEHRT outperforms all comparison machine learning models.

All rights reserved. No reuse allowed without permission.

Multimodal BEHRT




Figure 5. ROC curves M-BEHRT with the baselines for the prediction of disease-free survival 3 years after surgery, on the test set.

3.2.2 Ablation study

Mbave et al.

To better understand the contribution of each modality to the performance of M-BEHRT, we first compared it to the individual performance of its components Tabular BEHRT and Text BEHRT. Figure 6 reports ROC curves for all three approaches, on the test set. The optimal hyperparameters for Tabular BEHRT were a learning rate of 10^{-4} , a batch size of 16, Adam optimizer, and 5 epochs of training; for Text BEHRT they were a learning rate of 5.10^{-4} , a batch size of 32, Adam optimizer, and 99 epochs of training.

Although they use different information, Tabular BEHRT and Text BEHRT achieve similar performance on both tasks, highlighting that Text BEHRT can capture relevant information in unstructured medical reports. The combination of both models through cross-attention slightly improves their respective performance, demonstrating the synergistic effect of integrating the strengths of both Tabular and Text BEHRT into a single unified model.

We also performed an ablation study to better understand the contribution of each tabular modality to the performance of Tabular BEHRT. Figure 7 shows the areas under the ROC curves obtained on the test set when removing some of the modalities from Tabular BEHRT. This figures shows that dNPI contributes the most to the performance. However, the addition of the other features, in particular the remaining clinical features (including age and more notably therapies), increases performance substantially. Biological features contribute the least to performance, although they still contain information, as they allow for better-than-random prediction. However, it seems that this information is redundant with that captured by the other features. Performance also drops substantially if information about the nature of the medical visit (department and procedure) is omitted. These observations are consistant across both tasks.

Multimodal BEHRT

Models	AUC Scores
M-BEHRT	$0.77 \\ [0.70 - 0.84]$
NPI	$0.67 \\ [0.58 - 0.76]$
Random Forests	$0.67 \\ [0.58 - 0.75]$
Logistic Regression	$0.61 \\ [0.52 - 0.71]$
SVM	$0.61 \\ [0.55 - 0.72]$

Table 1. AUC scores comparison for M-BEHRT and the baselines for the prediction of disease-free survival 3 years after surgery, on the test set. M-BEHRT significantly outperforms the other methods (DeLong test in Figure S22 in the Supplementaty Material).

- We also provide in the Supplementary Material a comparison of Tabular BEHRT with baselines that only make use of tabular information (Figure S6 in the Supplementary Material) and a comparison of Text BEHRT with baselines that only make use of text information (Figure S7 in the Supplementary Material). In both cases, the transformer-based approaches outperformed all comparison partners.
- 429 3.2.3 Performance of M-BEHRT per cancer subtype
- Figure 8 presents the AUC-ROC of M-BEHRT on the test set, stratified by patient age, tumor grade,
- 431 molecular subtype, or node status. M-BEHRT is better at predicting DFS at three years on older patients,
- 432 with at least one affected lymph node. Stratification of results by NPI range is available on Figure S8 in the
- 433 Supplementary Material.

Mbave et al.

434 3.2.4 Model interpretation

- To better understand the predictions of M-BEHRT, we used the CAPTUM (32) implementation of the
- 436 integrated gradients (IG) method (33) to attribute the predictions of either Tabular BEHRT or Text BEHRT
- 437 to their input features. This allows us to highlight, for a given input sequence of visits, the elements that
- 438 contributed to the label.
- 439 Overall, Tabular BEHRT mainly uses NPI tokens to correctly identify relapse or death for samples from
- 440 the poor prognosis groups (VPPG and PPG), or to correctly identify DFS for patients from the good
- prognosis groups. What is more interesting, however, is to look at the tokens that Tabular BEHRT uses
- 442 to accurately predict relapse or death for samples from the good and moderate prognosis groups, as they
- 443 might provide critical insights into the aggressiveness and progression of the disease. They point towards
- 444 having a high number of multidisciplinary consultation meetings ("RCP" in French), a high number of
- 445 consultations overall, a second surgical procedure (within one year of the first one), or abnormal values for
- 446 the CA15-3 and the LYMP biological markers. Moreover, Tabular BEHRT uses well-documented factors
- 447 in the literature to predict a positive DFS status such as age.

All rights reserved. No reuse allowed without permission.

Mbaye et al.

Multimodal BEHRT



Figure 6. ROC curves comparing Tabular BEHRT and Text BEHRT against their combined model M-BEHRT for the prediction of disease-free survival 3 years after surgery, on the test set.

The interpretation of Text BEHRT's predictions shows that the model mostly relied on the entire sequence of the reports from the diagnosis to the index date to make its prediction, which is represented by the CLS token. We found this pattern in many true positive (correctly identifying death or relapse) samples. Moreover, Text BEHRT relies on reports that show information regarding the characterisation of a suspicious tumor, but this is not in and of itself indicative of a future relapse.

Finally, in order to gain a more global understanding of the model, we investigated the most predictive reports for a positive DFS status and for a negative DFS status. We set a threshold regarding the given attribution for each medical report. We collect all the reports with an attribution above this threshold. This yielded 921 reports that are predictive for negative DFS status in the entire corpus, and 1 720 reports that are predictive for positive DFS status. For each reports collection, we determined the 30 most frequent sequences (of 3 to 9 words) for both groups. We then listed the most frequent sequences for the DFS negative group that are not found in the DFS positive group. The resulting sequences of words can be found in Table 2.

Mbaye et al. Multimodal BEHRT




Figure 7. Ablation studies AUC-ROC on the test set for Tabular BEHRT. We present results for the full model (Tabular BEHRT), then using only one of the 4 modalities (dNPI, clinical features, biological features, medical visits), two modalities (dNPI+clinical or biological+visits), then removing one of the 4 modalities. Here "medical records" stands for features extracted extracted from the medical record headers, that is to say, visit department and procedure. Performance scores are presented on the test set.

461

462

463 464

465

466

467

468

469

470

471

Some of these sequences were obtained by combining overlapping sequences. We then plotted survival curves to compare patients that have reports containing one of these sentences and patients that do not. DFS is the event and the log-rank test is used to compare the populations. We show here two such curves, corresponding to sentences showing the most significant sequences: Figure 9 is for a sequence that translates to "breast in partial involution with less than 50% glandular tissue and Figure 10 is for a sequence that translates to "axillary lymphadenectomy".

For the first example (Figure 9), the survival curves suggest that patients with this feature are most likely to relapse than others. This feature defines a specific state of breast tissue where the glandular tissue is replaced by adipose tissue. This process naturally occurs with aging and after menopause. Therefore, this feature could have an impact on DFS simply because it is related to the patient's age, which is already

Multimodal BEHRT

1.00

Variable	N	AUC score (95% Conf. Int.)
Age		
<50 (162:16)	178	0.72(0.59 to 0.85)
>=50 (314:28)	342	0.78(0.69 to 0.87)
Molecular s/types		
Luminal (260:22)	282	0.74(0.62 to 0.85)
Her2+ (81:5)	86	0.85(0.74 to 0.96)
Tnbc (47:6)	53	0.85(0.73 to 0.97)
Nodes		
N0 (343:21)	364	0.73(0.64 to 0.83)
N+ (133:23)	156	0.76(0.65 to 0.87)
Grade		
Grade i (82:2)	84	0.59(0.19 to 0.99)
Grade ii (204:15)	219	0.79(0.68 to 0.90)
Grade iii (190:27)	217	0.74(0.64 to 0.85)

Figure 8. AUC-ROC of M-BEHRT on the test set stratified by patient age, cancer grade, molecular subtype and node status

0.00

0.25

0.50

AUC scores

0.75

- 472 a prognostic factor. However, when compared with 2 age groups (see Figure S11 in the Supplementary 473 Materials), it added more information on the survival than just > 50 years old and < 50 years old. Young 474 patients with this feature represent the worst prognostic groups.
- Although mammary involution is not a commonly used prognostic factor, several studies have showed a link between involution and breast cancer risk (34, 35); the underlying biological process could maybe also explain a hightened risk of relapse in young patients presenting abnormal mammary involution.
- The second plot (Figure 10) compared a population with the feature "axillary lymphadenectomy" and a population without. This feature is a mention of removing lymph nodes from the armpits. This information is associated with the potential affection of axillary nodes, which is found to be predictive for BC relapse.

4 DISCUSSION

481

482

483

484

485

486

487

Mbave et al.

In this paper, we proposed several novel deep learning architectures inspired by BEHRT to model patient trajectories using multimodal data extracted from EHRs. As the original BEHRT model, Tabular BEHRT considers structured data to describe each medical event. In addition, it considers multiple modalities (biological lab results, clinical information, department and procedure names) simultaneously. By contrast, in Text BEHRT each visit is described via the content of free text medical reports. Finally, M-BEHRT combines both models through cross-attention. Our work is motivated by applications to oncology, and applied to the prediction of disease-free survival for breast cancer patients.

Mbaye et al. Multimodal BEHRT

Sequence meaning in	Description
English English	Description
Breast in partial involution	Adipose involution is a natural process where glandular tissue is gradually
with less than 50% glandular	replaced by fat tissue, often as a result of aging or hormonal changes. Here,
tissue	the glandular tisuse makes up less than half of the total breast composition. While
	age is a risk factor for breast cancer, lobular involution is associated with a reduced
	risk of breast cancer (34, 35).
Previous treatment with	Treatment with human growth hormone can lead to the transmission of Creutzfeldt-
human growth hormone,	Jakob disease (CJD). This information is a medical administrative criterion
without risk factors for CJD	checked before surgery.
transmission	
With axillary	Until recently, axillary lymph node dissection was standard procedure in the case
lymphadenectomy	of involvement of lymph node in breast cancer, one of the main known risk factors
	for relapse or death (36).
Palpable mass	Palpable breast lumps are the most common presentation of breast disease.
Solu-Medrol, 80mg	Solu-Medrol is one brand name for methylprednisolone, a corticosteroid used in
	BC to manage the side effects of taxane-based chemotherapy (37).
Lovenox 0.4 mL	Lovenox is one brand name for enoxaparin sodium, a low molecular weight
	heparin used as anticoagulant medication. It is used to prevent and treat venous
	thromboembolisms, for which cancer patients are at higher risk (38).

Table 2. Most frequent sequences found in reports with high attribution for DFS- (relapse/death) instances but not for DFS+ instances, in Tabular BEHRT.

488 4.1 M-BEHRT achieves state-of-the-art or better prediction of DFS

495

496 497

498

499

500

501

502

503

504

505

506

507

508

509

Using very different information, Tabular BEHRT and Text BEHRT achieve AUCs on a held-out data set of 0.75 [0.66-0.83] and 0.75 [0.68-0.81], respectively, for the prediction of DFS 3 years after surgery. Combining them in M-BEHRT slightly increases predictive power, reaching an AUC of 0.77 [0.70-0.84]. All three architectures outperform classical machine learning methods. M-BEHRT is therefore able to capture the sequential aspect of patient data throughout their medical journey, resulting in improved performance.

To date, most of the multimodal prognosis models for breast cancer use various types of medical images, as well as sometimes genetics data, combined or not with tabular information (biological measurements, clinical features). Moreover, endpoints vary between studies: DFS, but also overall survival or recurrence (sometimes separated between local, regional and distant); which can be measured 3 years after surgery as in the present work, but also at different time points. Finally, different studies use different criteria inclusions. All in all, this makes comparing our performance to other studies challenging. However, we note that M-BEHRT achieves better performance for the prediction of DFS after three years than the recent work of Han et al. (6), which uses ultrasound and mammography images combined with clinical, pathological and radiographic characteristics and reports an AUC of 0.739 on a held-out test set. In addition, the performance of M-BEHRT is in the same ballpark as that of Rabinovici-Cohen et al. (5), which predict recurrence at five years in patients who receive neo-adjuvent chemotherapy (AUC of 0.75 on a held out data set) using clinical features, immunohistochemical markers, and multiparametric magnetic resonance imaging, or González-Castro et al. (9), which achieve an AUC of 0.81 also for predicting recurrence at five years, but considering all cancer patients and using clinical features, immunohistochemical markers, and descriptors of clinical history such as the number and type of therapies.

In order to further evaluate the ability of M-BEHRT to predict DFS, we also performed the same study, but for the prediction of DFS 5 years after surgery rather than 3. This results in a smaller data set of 5 192

Mbaye et al. Multimodal BEHRT




Figure 9. Survival plots for the sequence: "sein en involution adipeuse partielle avec contingent glandulaire inferieur a 50", (*breast in partial involution with less than 50% glandular tissue*), Present or Absent in patients reports

patients. The test set is the same as for DFS 3 years after surgery, but now contains 17.1% of negative samples. All results are available in the Supplementary Materials (Table S4 and Figure S10 for a description of the data, and Figures S11-17 for the results). Our observations are similar to those made on the prediction of DFS 3 years after surgery, although predicting DFS 3 years after surgery seems much easier than 5 years after surgery (AUC of 0.77 vs 0.69). This is in line with previous observations that earlier events are easier to predict than long-term ones (39).

513

514

515

516

517

All rights reserved. No reuse allowed without permission.

Mbaye et al.

Multimodal BEHRT




Figure 10. Survival plots for the sequence: "lymphadenectomie axillaire", (*axillary lymphadenectomy*), Present or Absent in patients reports.

518

519 520

521

522

523

524

525

We stratified the data based on features that are expected to define patients with similar prognoses (age, grade, number of lymph nodes involved, molecular subtype). We found that the prediction ability of M-BEHRT varies depending on subgroups and that the model works better on older patients with more aggressive disease (at least one lymph node involved). In addition, M-BEHRT is better at predicting relapse after 5 years than after 3 years for luminal tumors, suggesting that it correctly identifies predictive factors with long term influence for these tumors that tend to recur later than others (40).

There are however some limitations to the scope of our study. In particular, our findings are restricted to a very specific cohort of patients who received adjuvant chemotherapy. We also have not been able to validate

Mbaye et al. Multimodal BEHRT

our findings on an external validation group, due to privacy concerns limiting the access to EHR of other centers; it is possible that our models have captured idiosyncrasies of Institut Curie that do not apply to patients from other hospitals. However, our work shows that it is possible to learn from multimodal patient trajectories built from dynamic tabular data and the content of free-text reports written by practicioners at each medical visit, and paves the way for future research in understanding breast cancer prognostic factors.

4.2 M-BEHRT learns on small data sets

An important aspect of our study is that, unlike most work published to date using transformers for EHR data, which use millions of patients for pretraining and tens to hundreds of thousands of patients for fine-tuning (11, 13, 12), the datasets we use here are of much smaller sizes: about 15 000 patients for pretraining, and 5 000 to 8 000 patients for fine-tuning. That it is possible to apply such methods to much smaller data sets is very encouraging for future research, as many studies, especially on very specific diseases and endpoints, only have access to a limited number of patients.

However, despite the small sample size, our study has an advantage over those with larger datasets' studies because our learning data includes only adjuvant-treated breast cancer patients. This specificity has enabled the model to learn more precise embeddings and improve the accuracy of relapse prediction.

Keeping the same pretrained model, we experimented with further reducing the number of patients used for training the classifier. To this end, we created smaller training sets by randomly selecting subsets of the training data, starting from 10 samples, and compared on the test set the performance of Tabular BEHRT and classical machine learning algorithms trained on these small training sets. Our results, shown on Figure S20 in the Supplementary Material, show that Tabular BEHRT clearly outperforms the classical machine learning algorithms, especially random forests, in the few-shot learning setting (when training set sizes are very small), achieving better-than-random performance with as little as 10 training samples and outperforming NPI with a few hundred training samples. We attribute this performance to the ability of the pretraining phase to learn meaningful representations of patient trajectories.

4.3 M-BEHRT leverages the complementary nature of different modalities

In order to better understand the contribution of the different modalities to the performance of Tabular BEHRT, we conducted an ablation study. The results show that, with the exception of the biological features, excluding one modality or more substantially reduces model performance. This indicates that Tabular BEHRT has the ability to leverage the complementary nature of the different modalities. In addition, clinical features (dNPI, age, molecular subtype and therapy) contribute the most to performance. This observation is consistent with previous studies on breast cancer relapse prediction (41, 42).

Although others have found the results of routine laboratory tests to be very informative for predicting breast cancer endpoints (4, 41), our study did not see strong added value of including biological markers on DFS prediction. This is particularly surprising regarding cancer antigen CA 15-3, which has been found in several stiduies to correlate to poor prognosis (43, 44) and recurrence (45, 41). In addition, Kim et al. (41) found that an increase in leukocyte count (LEUK) has a protective effect against breast cancer recurrence and that an elevated neutrophil count (PN) is associated with recurrence, although another study (4) did not find a significant association between DFS and variables describing leukocyte counts and counts or percentages of leukocyte subtypes. However, these features not entirely uninformative, as restricting Tabular BEHRT to the biological features modality still yields better-than-random performance (AUC of 0.56 for T1 and 0.61 for T2). One possible explanation is that the information contained in the biological features is also captured by the other modalities, as their evolution might be consistent with

Mbaye et al. Multimodal BEHRT

- cancer severity or subtype, or the choice of therapy. Our study is also limited in the number of available laboratory variables, as markers that were found informative in previous studies, such as hemoglobin, total protein, serum glucose, alkaline phosphatase, or international normalized ratio (41, 4) were not available (or not for enough patients) in our data.
- Perhaps surprisingly, we do not see the same drastic increase in performance between Tabular BEHRT and M-BEHRT as others have observed in multimodal prediction of breast cancer prognosis when augmenting clinical data with imaging data (5, 6), although Text BEHRT leverages medical reports from radiologists or cytopathologists, which are based on medical images. Although this could be due to the aforementioned limitations of Text BEHRT, this could also be because Tabular BEHRT already achieves much better performance than models based solely on static clinical data.

578 4.4 M-BEHRT model interpretation points to possible prognostic factors

- The interpretation of M-BEHRT models through the integrated gradients method highlighted that Tabular BEHRT relies on well-documented prognostic features such as the age or the NPI (46, 2) to predict DFS status. Additionnally, the model uses features that indicate a more aggressive breast cancer (number of multidisciplinary meetings, number of consultations, or a second surgical procedure), which can not be necessarily be considered as causes of cancer relapse but suggest a more difficult-to-treat cancer.
- Regarding Text BEHRT, the model seems to rely mainly on reports that contain symptoms-related information or reports from imagery. When they occur before the first surgery, these information are to be expected, as we are studying a cohort of patients treated for breast cancer. However, if they occur after the first surgery, these features can indicate further investigations that are warranted by the difficulty to treat the primary tumor.
- Let us note however that while deep learning model interpretation is still somewhat limited, it has the 589 potential to offer a much more comprehensive interpretation of the roles played by different elements in 590 the data, given how rich the data is. Moreover, the features that are highlighted as strongly contributing 591 towards one label or the other are only doing so in conjunction with other features, which might be different 592 from patient to patient. Moreover, the embedding pooling method that we have used to derive reports 593 embeddings from their contents does not help with interpretability, as it does not allow to pinpoint specific 594 parts of a medical report. Nevertheless, several potentially interesting text features (such as high mammary 595 involution or axillary dissection) have been highlighted for their contribution to M-BEHRT predictions. 596 Even though it is not yet clear how these features can be used as prognostic factors and incorporated in a 597 model usable in the clinic, survival curves show that they are indeed informative of DFS even taken on 598 their own. 599

4.5 Challenges of learning from long sequences of rich events

600

601

602

603

604

605

606

607 608 In our approach, there is a tradeoff between the number of visits that can be considered and the amount of information that can be used to describe each visit, because the underlying BERT architecture is limited to processing 512 tokens. This number is arbitrary, but constrained by the memory usage of the self-attention mechanism. We have found this number to be sufficient for the DFS prediction tasks at hand and the available features and modalities. However, this might be too small for other applications, in which case one might want to use approaches that approximate the self-attention matrices so as to reduce their memory footprint, such as Big Bird (22) or Nyströmformer (23). In the present study, M-BEHRT outperforms both NPI and classical ML baselines, suggesting its ability to capture the structure of EHR data.

Multimodal BEHRT

To the best of our knowledge, ours is the first study to use entire free text medical reports (in a language other than English) for breast cancer prognosis. There are several limitations to our approach. First, we used token embeddings learned on French clinical text that are not specific to breast cancer; it is possible that pretraining on breast cancer clinical text could improve the performance of our model. However, this requires considerable resources, both in terms of amount of clinical records available and computing power. Second, we build medical records embedding by simply pooling all token embeddings of a record, which is likely not be optimal for capturing the information contained in a report. Several authors have proposed using convolutional neural networks (CNN) or bidirectional long-short term memory architectures (Bi-LSTM) on top of token embeddings (20, 47, 48), which typically helps capturing the structure of text documents and could be an interesting future direction to explore for this research. Despite these shortcomings, our results demonstrate the ability of Text BEHRT to capture relevant information, as it

621 Finally, M-BEHRT uses a cross-attention module to perform the multimodal fusion between 622 Tabular BEHRT and Text BEHRT. This approach allows the contextual integration of information from both transformers, i.e, that each model can attend information from the other model, and thus enable a 623 624 better exploitation of the complementarity between inputs. However, this requires that both tabular data 625 and text data embeddings have the same size, and forced us to reduce the dimensionality of the embedding of sequences of reportsfrom 768 (as provided by DrBERT) to 144 through a linear layer. This may result 626 627 in an additional reduction of available information. However, this still results in a slight improvement of overall performance. 628

4.6 Conclusion

performs on par with Tabular BEHRT.

Mbave et al.

609

610

611 612

613

614 615

616 617

618 619

620

629

Overall, our study highlights the potential to predict DFS using solely longitudinal sequence of medical visits and evolution of clinical information and biological measurements. To the best of our knowledge, this is the first study predicting breast cancer endpoints from sequences of EHR data, whether considering solely multimodal dynamic tabular data, solely the contents of free-text reports, or combining both. Our results underscore the usefulness of such data for future research on prognosis modeling, and outline the importance of integrating medical information collected over time to gain previously unknown insights into the understanding of breast cancer evolution.

CONFLICT OF INTEREST STATEMENT

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ETHICS STATEMENT

- 639 The studies involving human participants were reviewed and approved by the Institutional Review Board
- 640 of Institut Curie (Paris, France). The patients/participants provided their written informed consent to
- 641 participate in this study.

AUTHOR CONTRIBUTIONS

- 642 Conceptualization: CAA, MD, MRZ, NMB
- Data curation: JG, ED, AHP, AT

Mbaye et al. Multimodal BEHRT

- 644 Formal analysis: NMB
- 645 Funding acquisition: CAA, MRZ, FR
- 646 Investigation: NMB, AT
- 647 Methodology: CAA, MD, MRZ, NMB
- 648 Project administration: CAA, NMB
- 649 Resources: JG
- 650 Software: NMB
- 651 Supervision: CAA, MRZ
- 652 Visualization: NMB
- 653 Writing original draft: CAA, NMB
- Writing review & editing: CAA, NMB, MRZ, MD

FUNDING

- 655 This project has received funding from the European Union's Horizon 2020 research and innovation
- 656 programme under the Marie Skłodowska-Curie grant agreement No 813533 and from the French
- 657 government under management of Agence Nationale de la Recherche as part of the "Investissements
- 658 d'avenir" program, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute).

ACKNOWLEDGMENTS

- 659 The authors thank Éric Daoud, Antoine Recanati and Charles Vesteghem for fruitful discussion and Johan
- 660 Archinard for the technical environment maintenance.

DATA AVAILABILITY STATEMENT

- 661 Electronic health records are considered sensitive data in the EU by the General Data Protection Regulation
- 662 and cannot be shared via public deposition because of legal restriction in place to protect patient
- 663 confidentiality. Data can only be accessed once approval has been obtained through the Institutional
- 664 Review Board of Institut Curie.

REFERENCES

- 1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global cancer observatory: Cancer today (version 1.1) (2024). Lyon, France, https://gco.iarc.who.int/today.
- **2** .Haybittle J, Blamey R, Elston C, Johnson J, Doyle P, Campbell F, et al. A prognostic index in primary breast cancer. *British journal of cancer* **45** (1982) 361–366.
- 3 .Phung MT, Tin Tin S, Elwood JM. Prognostic models for breast cancer: a systematic review. *BMC* cancer **19** (2019) 1–18.
- 4. Zhu Z, Li L, Ye Z, Fu T, Du Y, Shi A, et al. Prognostic value of routine laboratory variables in prediction of breast cancer recurrence. *Scientific Reports* 7 (2017). doi:10.1038/s41598-017-08240-2.

Multimodal BEHRT

- 673 5 .Rabinovici-Cohen S, Fernández XM, Grandal Rejo B, Hexter E, Hijano Cubelos O, Pajula J, et al. Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant 674 Chemotherapy. Cancers 14 (2022) 3848. doi:10.3390/cancers14163848. 675
- 6. Han J, Hua H, Fei J, Liu J, Guo Y, Ma W, et al. Prediction of disease-free survival in breast cancer 676 using deep learning with ultrasound and mammography: A multicenter study. Clinical Breast Cancer 677 678 (2024). doi:10.1016/j.clbc.2024.01.005.
- 679 7. Yao Y, Lv Y, Tong L, Liang Y, Xi S, Ji B, et al. Icsda: a multi-modal deep learning model to predict breast cancer recurrence and metastasis risk by integrating pathological, clinical and gene expression 680 681 data. Briefings in Bioinformatics 23 (2022). doi:10.1093/bib/bbac448.
- 8. Zeng Z, Yao L, Roy A, Li X, Espino S, Clare SE, et al. Identifying breast cancer distant recurrences 682 from electronic health records using machine learning. Journal of Healthcare Informatics Research 3 683 (2019) 283-299. doi:10.1007/s41666-019-00046-3. 684
- 9 .González-Castro L, Chávez M, Duflot P, Bleret V, Martin AG, Zobel M, et al. Machine learning 685 algorithms to predict breast cancer recurrence using structured and unstructured sources from electronic 686 health records. Cancers 15 (2023) 2741. doi:10.3390/cancers15102741. 687
- 10 .Devlin J, Chang MW, Lee K, Toutanova K. BERT: Pre-training of Deep Bidirectional Transformers for 688 Language Understanding. Proceedings of the 2019 Conference of the North American Chapter of the 689 Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short 690 Papers) (Minneapolis, Minnesota: Association for Computational Linguistics) (2019), 4171–4186. 691 doi:10.18653/v1/N19-1423. 692
- 11 .Li Y, Rao S, Solares JRA, Hassaine A, Ramakrishnan R, Canoy D, et al. BEHRT: Transformer for 693 Electronic Health Records. Scientific Reports 10 (2020) 7155. doi:10.1038/s41598-020-62922-y. 694 695 Number: 1 Publisher: Nature Publishing Group.
- 12 .Pang C, Jiang X, Kalluri KS, Spotnitz M, Chen R, Perotte A, et al. Cehr-bert: Incorporating temporal 696 information from structured ehr data to improve prediction tasks. Roy S, Pfohl S, Rocheteau E, Tadesse 697 GA, Oala L, Falck F, et al., editors, *Proceedings of Machine Learning for Health* (PMLR) (2021), 698 Proceedings of Machine Learning Research, vol. 158, 239–260. 699
- 13 .Rasmy L, Xiang Y, Xie Z, Tao C, Zhi D. Med-bert: pretrained contextualized embeddings on large-700 scale structured electronic health records for disease prediction. npj Digital Medicine 4 (2021) 86. 701 702 doi:10.1038/s41746-021-00455-y.
- 14 .Rao S, Mamouei M, Salimi-Khorshidi G, Li Y, Ramakrishnan R, Hassaine A, et al. Targeted-BEHRT: 703 Deep Learning for Observational Causal Inference on Longitudinal Electronic Health Records. IEEE 704 Transactions on Neural Networks and Learning Systems (2022) 1–12. doi:10.1109/TNNLS.2022. 705 706 3183864. Conference Name: IEEE Transactions on Neural Networks and Learning Systems.
- 15 .Li Y, Mamouei M, Salimi-Khorshidi G, Rao S, Hassaine A, Canoy D, et al. Hi-BEHRT: Hierarchical 707 708 Transformer-Based Model for Accurate Prediction of Clinical Events Using Multimodal Longitudinal 709 Electronic Health Records. IEEE Journal of Biomedical and Health Informatics 27 (2023) 1106-1117. doi:10.1109/JBHI.2022.3224727. Conference Name: IEEE Journal of Biomedical and Health 710 Informatics. 711
- 712 16 .Blamey R, Ellis I, Pinder S, Lee A, Macmillan R, Morgan D, et al. Survival of invasive breast cancer according to the nottingham prognostic index in cases diagnosed in 1990–1999. European journal of 713 714 cancer 43 (2007) 1548-1555.
- 17 .Grossman Liu L, Grossman RH, Mitchell EG, Weng C, Natarajan K, Hripcsak G, et al. A deep database 715 of medical abbreviations and acronyms for natural language processing. Scientific Data 8 (2021). 716 717

doi:10.1038/s41597-021-00929-4.

Mbave et al.

Multimodal BEHRT

18 Vaswani A, Shazeer N, Parmar N, Uszkoreit J, Jones L, Gomez AN, et al. Attention is All you Need.

- Guyon I, Luxburg UV, Bengio S, Wallach H, Fergus R, Vishwanathan S, et al., editors, Advances in 719
- Neural Information Processing Systems 30 (Curran Associates, Inc.) (2017), 5998–6008. 720

Mbave et al.

- 721 19 .Chen CFR, Fan Q, Panda R. Crossvit: Cross-attention multi-scale vision transformer for image classification. Proceedings of the IEEE/CVF international conference on computer vision (2021), 722 723 357-366.
- 20 .Gao S, Alawad M, Young MT, Gounley J, Schaefferkoetter N, Yoon HJ, et al. Limitations of 724 transformers on clinical text classification. IEEE Journal of Biomedical and Health Informatics 725 **25** (2021) 3596–3607. 726
- 21 .Park H, Vyas Y, Shah K. Efficient classification of long documents using transformers. Muresan 727
- 728 S, Nakov P, Villavicencio A, editors, Proceedings of the 60th Annual Meeting of the Association
- 729 for Computational Linguistics (Volume 2: Short Papers) (Association for Computational Linguistics) (2022), 702-709.730
- 22 .Zaheer M, Guruganesh G, Dubey KA, Ainslie J, Alberti C, Ontanon S, et al. Big bird: Transformers for 731 longer sequences. Advances in neural information processing systems (2020), vol. 33, 17283–17297. 732
- 23 .Xiong Y, Zeng Z, Chakraborty R, Tan M, Fung G, Li Y, et al. Nyströmformer: A nyström-based 733 algorithm for approximating self-attention. Proceedings of the AAAI Conference on Artificial 734 Intelligence (2021), vol. 35, 14138-14148. 735
- 24 .Pappagari R, Zelasko P, Villalba J, Carmiel Y, Dehak N. Hierarchical transformers for long document 736 737 classification. 2019 IEEE Automatic Speech Recognition and Understanding Workshop (ASRU) (2019), 838-844. 738
- 25 .Li C, Yates A, MacAvaney S, He B, Sun Y. PARADE: Passage representation aggregation for document 739 reranking. ACM Transactions on Information Systems 42 (2023) 1–26. 740
- 26 .Labrak Y, Bazoge A, Dufour R, Rouvier M, Morin E, Daille B, et al. DrBERT: A Robust Pre-trained 741
- Model in French for Biomedical and Clinical domains. Proceedings of the 61th Annual Meeting of the 742
- Association for Computational Linguistics (ACL'23), Long Paper (Toronto, Canada: Association for 743 Computational Linguistics) (2023), 16207–16221. 744
- 27 .Liu Y, Ott M, Goyal N, Du J, Joshi M, Chen D, et al. Roberta: A robustly optimized bert pretraining 745 approach. arXiv preprint arXiv:1907.11692 (2019). 746
- 28 .Bergstra J, Yamins D, Cox DD. Hyperopt: A python library for optimizing the hyperparameters of 747 machine learning algorithms. van der Walt S, Millman J, Huff K, editors, *Proceedings of the 12th* 748
- 749 Python in Science Conference (2013), 13 – 19. doi:10.25080/Majora-8b375195-003.
- 29 .Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: Machine 750 learning in Python. Journal of Machine Learning Research 12 (2011) 2825–2830. 751
- 30 .Honnibal M, Montani I, Van Landeghem S, Boyd A. spaCy: Industrial-strength natural language 752 processing in python (2020). Doi:10.5281/zenodo.1212303, https://spacy.io/. 753
- 31 Paszke A, Gross S, Massa F, Lerer A, Bradbury J, Chanan G, et al. Pytorch: An imperative style, 754
- high-performance deep learning library. Wallach H, Larochelle H, Beygelzimer A, d'Alché-Buc F, Fox 755
- E, Garnett R, editors, Advances in Neural Information Processing Systems 32 (Curran Associates, Inc.) 756 (2019), 8024-8035. 757
- 758 32 .[Dataset] Kokhlikyan N, Miglani V, Martin M, Wang E, Alsallakh B, Reynolds J, et al. Captum: A unified and generic model interpretability library for pytorch (2020). 759
- 33 .Sundararajan M, Taly A, Yan Q. Axiomatic attribution for deep networks. *Proceedings of the 34th* 760 International Conference on Machine Learning - Volume 70 (JMLR.org) (2017), ICML'17, 3319–3328. 761

Mbaye et al. Multimodal BEHRT

- 34 .Radisky DC, Hartmann LC. Mammary involution and breast cancer risk: transgenic models and clinical studies. *Journal of mammary gland biology and neoplasia* 14 (2009) 181–191.
- 35 .Bodelon C, Oh H, Derkach A, Sampson JN, Sprague BL, Vacek P, et al. Polygenic risk score for the
 prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast. *NPJ breast cancer* 6 (2020) 41.
- 36 .Kelley K, Sener SF. Who still needs surgical staging of the axilla for invasive breast cancer? *Journal of Surgical Oncology* (2024). doi:10.1002/jso.27753.
- 769 37 .Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the european organization for research and treatment of cancer investigational drug branch for breast cancer. *Journal of Clinical Oncology* 15 (1997) 3149–3155. doi:10.1200/jco.1997.15.9.3149.
- 38 .Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation strategies in patients with cancer. *Journal of the American College of Cardiology* **73** (2019) 1336–1349. doi:10.1016/j.jacc.2019.01.017.
- 39 .Witteveen A, Vliegen IMH, Sonke GS, Klaase JM, IJzerman MJ, Siesling S. Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. *Breast Cancer Research and Treatment* 152 (2015) 627–636. doi:10.1007/s10549-015-3490-4.
- 40 .Ignatov A, Eggemann H, Burger E, Ignatov T. Patterns of breast cancer relapse in accordance to biological subtype. *Journal of Cancer Research and Clinical Oncology* 144 (2018) 1347–1355.
- 41 .Kim JY, Lee YS, Yu J, Park Y, Lee SK, Lee M, et al. Deep learning-based prediction model for breast cancer recurrence using adjuvant breast cancer cohort in tertiary cancer center registry. *Frontiers in Oncology* 11 (2021). doi:10.3389/fonc.2021.596364.
- 42 .Dai W, Li Y, Mo S, Feng Y, Zhang L, Xu Y, et al. A robust gene signature for the prediction of early relapse in stage i–iii colon cancer. *Molecular Oncology* 12 (2018) 463–475. doi:https://doi.org/10.1002/1878-0261.12175.
- 43 .McLaughlin R, McGrath J, Grimes H, Given H. The prognostic value of the tumor marker ca 15–3 at initial diagnosis of patients with breast cancer. *The International Journal of Biological Markers* 15 (2000) 340–342. doi:10.1177/172460080001500412.
- 44 .Chourin S, Georgescu D, Gray C, Guillemet C, Loeb A, Veyret C, et al. Value of ca 15-3 determination in the initial management of breast cancer patients. *Annals of Oncology* 20 (2009) 962–964. doi:10. 1093/annonc/mdp061.
- 45 .De Cock L, Heylen J, Wildiers A, Punie K, Smeets A, Weltens C, et al. Detection of secondary metastatic breast cancer by measurement of plasma ca 15.3. *ESMO Open* 6 (2021) 100203. doi:10. 1016/j.esmoop.2021.100203.
- 46 .Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the american college of surgeons. *Cancer* 45 (1980) 2917–2924.
- 47 .D'Costa A, Denkovski S, Malyska M, Moon SY, Rufino B, Yang Z, et al. Multiple sclerosis severity classification from clinical text. *Proceedings of the 3rd Clinical Natural Language Processing Workshop* (2020), 7–23.
- 48 .Hui Y, Du L, Lin S, Qu Y, Cao D. Extraction and classification of tem medical records based on bert and bi-lstm with attention mechanism. 2020 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) (IEEE) (2020), 1626–1631. doi:10.1109/bibm49941.2020.9313359.



Supplementary Material to Multimodal BEHRT: Transformers for Multimodal Electronical Health Records

SUPPLEMENTARY TABLES AND FIGURES

Feature	Normal range	Mean value \pm std	missing
CA15-3 (U/ml)	N < 30	63.39 ± 484.44	6 390
LEUK (g/l)	4 < N < 10	6.99 ± 6.82	2525
PN(g/l)	1.7 < N < 7	718.85 ± 1789.66	9419
LYMP (g/l)	1.4 < N < 4	289.63 ± 714.26	9448
MONO (g/l)	0.2 < N < 1	33.29 ± 123.59	3675

Table S1. Normal ranges for the biological features

Features		Entire dataset		Dataset for DFS at 3 years	
		Mean \pm std	N	Mean \pm std	N
Age	< 50	58 ± 12	3982	56 ± 12	2493
	≥ 50		11168		5596
	Luminal		9979		4 866
BC subtype	TNBC		1041		642
BC subtype	HER2+/HR+		681		587
	HER2+/HR-		480		415
	I		3473		1688
Grades	II		5911		3057
	III		3119		2044
Nodes	N0	0.93 ± 2.49	9 463	1.07 ± 2.74	4 899
	N+	0.33 ± 2.43	4045		2405
Tumor	Clinical	16.89 ± 12.70		17.36 ± 12.97	
size	Pathological	15.04 ± 12.75		15.63 ± 12.90	
(mm)	CA 15-3 (U/ml)	63.39 ± 484.44	8 760	62.85 ± 535.76	3 826
Biological values	LEUK (g/l)	6.99 ± 6.82	12625	6.90 ± 7.49	6419
	PN(g/l)	718.85 ± 1789.66	5731	976.17 ± 2007.52	2385
	LYMP (g/l)	289.63 ± 714.26	5702	405.84 ± 820.08	2373
	MONO(g/l)	33.29 ± 123.59	11475	37.54 ± 131.79	5821
Medical reports	visits	46 ± 33		25 ± 10	
	reports	62 ± 50		34 ± 15	
	words/report	172 ± 41		159 ± 37	

Table S2. Descriptive statistics of the data used in this study, for the full cohort of 15 150 patients, as well as the data set of patients uncensored 3 years after surgery.

Multimodal BEHRT Supplementary Material




Figure S1. Binarization of biological features into two values, 1 and 2. For each of the 5 biological features, the dashed red lines delineate the normal range, highlighted in red, and mapped to 2, from the abnormal range, highlighted in green, and mapped to 1

Therapies	Sub-therapies
	Lumpectomy
Surgery	Mastectomy
	Axillary node dissection
	Sentinel node biopsy
Radiotherapy	Axillary irradiation
	Internal mammary chain irradiation
	Mammary gland/chest wall irradiation
	Supra/sub-clavicular irradiation
Hormone therapy	Tamoxifen
	Aromatase
	LHRH agonist
Anti-HER2 therapy	Trastuzumab
	Pertuzumab
	Lapatinib

Table S3. List of possible therapies and sub-therapies in our data.

Multimodal BEHRT Supplementary Material




Figure S2. Institut Curie Therapeutic Protocol




Figure S3. Text preprocessing pipeline.




Figure S4. Distribution of the number of tokens per patient trajectory, for the prediction of disease-free survival 3 years after surgery. 859 samples exceed the maximum sequence length for Tabular BEHRT (512 tokens). This represents an average of 10 visits per patient that are not considered by Tabular BEHRT.

Multimodal BEHRT Supplementary Material

Validation scores




Figure S5. Precision scores for the Masked Language Model (pre-training of Tabular BEHRT). The baseline scores are obtained from the MLM ran on shuffled sequences.

Training scores

Baseline

Multimodal BEHRT Supplementary Material




Figure S6. ROC curves for baselines and Tabular BEHRT, for predicting disease-free survival 3 years after surgery.






Figure S7. ROC curves for baselines and Text BEHRT, for predicting disease-free survival 3 years after surgery.




Figure S8. AUC-ROC of M-BEHRT stratified by NPI, for predicting disease-free survival 3 years after surgery.

Features		Entire datase	et .	Dataset for DFS at 3 years		Dataset for DFS at 5 years	
		Mean \pm std	N	Mean \pm std	N	Mean \pm std	N
Age	< 50	58 ± 12	3 982	56 ± 12	2493	55 ± 13	1725
	≥ 50	00 ± 12	11168		5596		3467
BC subtype	Luminal		9 9 7 9		4866		2 930
	TNBC		1041		642		446
	HER2+/HR+		681		587		482
	HER2+/HR-		480		415		330
Grades	I		3473		1688		1 016
	II		5911		3057		1941
	III		3119		2044		1462
Nodes	N0	0.93 ± 2.49	9463	1.07 ± 2.74	4899	1.18 ± 3.01	3 132
	N+	0.33 ± 2.43	4045		2405		1597
Tumor	Clinical	16.89 ± 12.70		17.36 ± 12.97		17.78 ± 13.18	
size (mm)	Pathological	15.04 ± 12.75		15.63 ± 12.90		16.17 ± 12.94	
Biological values	CA 15-3 (U/ml)	63.39 ± 484.44	8 760	62.85 ± 535.76	3826	75.34 ± 617.09	2256
	LEUK (g/l)	6.99 ± 6.82	12625	6.90 ± 7.49	6419	6.75 ± 3.60	3916
	PN (g/l)	718.85 ± 1789.66	5731	976.17 ± 2007.52	2385	1105.76 ± 2093.81	1365
	LYMP (g/l)	289.63 ± 714.26	5702	405.84 ± 820.08	2373	463.92 ± 862.37	1375
	MONO (g/l)	33.29 ± 123.59	11475	37.54 ± 131.79	5821	33.29 ± 123.59	3489
Medical reports	visits	46 ± 33		25 ± 10		25 ± 10	
	reports	62 ± 50		34 ± 15		34 ± 15	
	words/report	172 ± 41		159 ± 37		159 ± 37	

Table S4. Descriptive statistics of the data sets used in this study, for the full cohort of 15 150 patients, as well as the data set of patients uncensored 3 years and 5 years after surgery.




Figure S9. Survival plots for the presence/absence of the sentence meaning "breast in partial involution with less than 50% glandular tissue", combined with the feature "age" (>50 vs <50).




Figure S10. Distribution of the number of tokens per patient trajectory, for the prediction of disease-free survival 5 years after surgery. 610 samples exceed the maximum sequence length for Tabular BEHRT (512 tokens). This represents an average of 10 visits per patient that are not considered by Tabular BEHRT.




Figure S11. ROC curves for baselines and Tabular BEHRT, for predicting disease-free survival 5 years after surgery.




Figure S12. ROC curves for baselines and Text BEHRT, for predicting disease-free survival 5 years after surgery.




Figure S13. ROC curves M-BEHRT and baselines, for predicting disease-free survival 5 years after surgery.



Figure S14. ROC curves comparing Tabular BEHRT and Text BEHRT against their combined model M-BEHRT, for the prediction of disease-free survival 5 years after surgery.




Figure S15. Ablation studies AUC-ROC on the test set for Tabular BEHRT, for the prediction of diseasefree survival 5 years after surgery. We present results for the full model (Tabular BEHRT), then using only one of the 4 modalities (dNPI, clinical features, biological features, medical visits), two modalities (dNPI+clinical or biological+visits), then removing one of the 4 modalities. Here "medical records" stands for features extracted extracted from the medical record headers, that is to say, visit department and procedure. Performance scores are presented on the test set.

Variable	N	AUC score	(95% Conf. Int.)
Age			
<50 (150:28)	178	0.63(0.53	to 0.74)
>=50 (281:61)	342	0.71(0.63	to 0.78)
Molecular s/types			
Luminal (232:50)	282	0.69(0.61	to 0.78)
Her2+ (74:12)	86	0.61(0.37	to 0.85)
Tnbc (44:9)	53	0.64(0.46	to 0.82)
Nodes			
N0 (310:54)	364	0.64(0.56	to 0.72)
N+ (121:35)	156	0.73(0.63	to 0.83)
Grade			
Grade i (75:9)	84	0.70(0.57	to 0.84)
Grade ii (184:35)	219	0.61(0.50	to 0.72)
Grade iii (172:45)	217	0.72(0.63	to 0.80)




Figure S16. AUC-ROC of M-BEHRT stratified by patient age, cancer grade, molecular subtype and node status, for the prediction of disease-free survival 5 years after surgery.

0.50

AUC scores

0.75


1.00

Variable	N	AUC score	(95%	Conf.	Int.)
VPPG					
DNPI >= 6.4 (10:7)	17	0.61(0.47	to 0	.75)	
PPG					
5.4 <= DNPI < 6.4 (31:11)	42	0.67(0.55	to 0	.80)	
MPGI					
4.4 <= DNPI < 5.4 (121:21)	142	0.62(0.48	to 0	.76)	
MPGII					
3.4 <= DNPI < 4.4 (71:18)	89	0.70(0.57	to 0	.83)	
GPG					
2.4 <= DNPI < 3.4 (137:21)	158	0.83(0.69	to 0	.98)	
EPG					

Figure S17. AUC-ROC of M-BEHRT stratified by NPI, for predicting disease-free survival 5 years after surgery.

72 0.69(0.41 to 0.96)

DNPI <=2.4 (61:11)






Figure S18. AUC-ROC on the test set of Tabular BEHRT, random forests, support vector classifier, and logistic regression trained on subsets of the training set of increasing sizes (x-axis), for the prediction of disease-free survival 3 (top) or 5 (bottom) years after surgery.




Figure S19. AUC scores comparison between M-BEHRT and the baselines for the prediction of disease-free survival 3 years after the surgery on the test set.

perpetuity.
All rights reserved. No reuse allowed without permission.



Supplementary Text to Multimodal BEHRT: Transformers for Multimodal Electronical Health Records

1 PREPROCESSING OF FREE TEXT

Removing proper nouns is one of the key step of the preprocessing pipeline. This is important as specific doctor names may serve as proxy for the DFS classification, for example, when a doctor mostly handles severe cases. Patient names are already excluded from the reports, which had been anonymized before we accessed them. The first stage of this process consists in using part-of-speech tagging to remove proper nouns tags that follow titles such as Dr, M. ("Mr" in English), Mme ("Mrs" in English). However, proper nouns may appear without a title. We thus further constructed a list of proper nouns to remove from the text. We first built a list of names of Institut Curie's health practicioners, obtained through the public directory of practicioners Cur (Accessed: 2023-01-30) as retrieved in 2023, and therefore only partially matching practicioners that were involved in the care of patients in the 2005–2012 period covered by our cohort). We additionally considered surnames given at least 30 times in France from 1891 to 2000 (n=218 912) and first names given at least 20 times from 1946 to 2022 in France (n=36 964), as provided by Institut National de La Statistique et des Etudes Econonomiques (INSEE) (Ins (Accessed: 2023-01-30), INS (Accessed: 2023-01-30)). We then removed from this list the proper names that correspond to disease names, such as Paget.

One other main difficulty that occur with free-text reports is the high number of typos. To address this issue, we used the pyspellchecker spell checking algorithm Barus (2023) which identifies, for each word of the corpus that is not found in a given dictionary, the most likely correct replacement for this presumably misspelled word. For effective spellchecking, it is crucial to have a rich dictionary that contains medical jargon. Therefore, we augmented the French vocabulary from OpenSubtitles Lison and Tiedemann (2016) (implemented by default in pyspellchecker) with the contents of the French open dictionary Usito ush (Accessed: 2023-01-30), as well as the 3 184 words from a French online medical dictionary Thomsen (Accessed: 2023-01-30), the CAS corpus of French clinical cases Grabar et al. (2018) which contains over 397 000 word occurences, a list of drug names in French vid (Accessed: 2023-01-30), and two lists of French medical abbreviations specific to oncology moz (2020); Poletto (2023). If, following this step, any words from the dictionary remain unidentified, we replaced them with the most likely correct spelling suggestion from Wikipedia wik (Accessed: 2023-01-30).

2 TEXT BEHRT INTERPRETATION

We choose to analyze the most frequent sequences for the DFS negative cohort that are not found in the DFS positive cohort. We ended up with the following sequences of words, some of which have been obtained with the overlapping resulting sequences:

- "sein en involution adipeuse partielle avec contingent glandulaire inferieur a 50", (breast in partial adipose involution with less than 50% glandular contingent)
- "Traitement anterieur par hormone de croissance extractible non facteurs de risque de transmission de la mcj", (*Previous treatment with extractable growth hormone without risk factors for mcj transmission*)

All rights reserved. No reuse allowed without permission.

Multimodal BEHRT Supplementary Text

- "[avec] lymphadenectomie axillaire", (with axillary lymphadenectomy)
- "syndrome de masse", (mass syndrom)
- "[j1] solumedrol 80mg", (solumedrol 80mg)
- "lovenox 0 4 ml", (*lovenox 0 4 ml*)

REFERENCES

Curie - annuaire 2023 (Accessed: 2023-01-30). https://curie.fr/annuaire-medecins. Insee noms (Accessed: 2023-01-30). https://www.insee.fr/fr/statistiques/3536630. Insee prenoms (Accessed: 2023-01-30). https://www.insee.fr/fr/statistiques/7633685?sommaire=7635552.

Barus T. pyspellchecker – Pure python spell checker based on work by Peter Norvig (2023). https://pypi.org/project/pyspellchecker.

Lison P, Tiedemann J. OpenSubtitles2016: Extracting large parallel corpora from movie and TV subtitles. Calzolari N, Choukri K, Declerck T, Goggi S, Grobelnik M, Maegaard B, et al., editors, *Proceedings of the Tenth International Conference on Language Resources and Evaluation (LREC'16)* (Portorož, Slovenia: European Language Resources Association (ELRA)) (2016), 923–929.

Usito, dictionnaire général de la langue française (Accessed: 2023-01-30). Université de Sherbrooke https://usito.usherbrooke.ca/.

Thomsen C. Dictionnaire Médical (Accessed: 2023-01-30). https://www.dictionnaire-medical.fr/.

Grabar N, Claveau V, Dalloux C. CAS: French corpus with clinical cases. Lavelli A, Minard AL, Rinaldi F, editors, *Proceedings of the Ninth International Workshop on Health Text Mining and Information Analysis* (Brussels, Belgium: Association for Computational Linguistics) (2018), 122–128. doi:10. 18653/v1/W18-5614.

Le Dictionnaire VIDAL (Accessed: 2023-01-30). https://www.vidal.fr/medicaments.html. Oncopod - abréviations pour l'oncologie (2020). https://www.mozocare.com/fr/oncopod/chemotherapy/abbreviations/(Accessed: 2023-01-30), Mozocare.

Poletto B. Glossaire info cancer (2023). https://www.arcagy.org/infocancer/cms/glossaire, (Accessed: 2023-01-30).

Wikipédia - l'encyclopédie libre (Accessed: 2023-01-30). https://fr.wikipedia.org.